Engineering Biology is the cutting edge of #biotech – and many BioIndustry Association (BIA) members are breaking boundaries in this space. Check out this video featuring Synthace Prokarium and Green Biologics Ltd. - bit.ly/2AelxhY #synbio

Prokarium today announced the appointment of Kristen Albright as new CEO: bit.ly/3734xKU. As Prokarium accelerates its drug development efforts within #oncology, Kristen brings extensive financing & strategic leadership experience that will propel the company forward.

Prokarium announces the appointment of Thomas Eldered as Chairman of the Board: bit.ly/3FlIlLZ. With 30+ years of experience, including co-founding & managing Recipharm, one of the 5 largest CDMOs in the world, Thomas will be a valuable addition to the Prokarium team.

Prokarium announces the promotion of Livija Deban to Chief Scientific Officer: prokarium.com/prokarium-prom…. Previously serving as VP of Research at Prokarium, Dr. Deban will continue to drive the development of the company’s immuno-oncology portfolio.

🫧 May was Bladder Cancer Awareness Month 🫧 The team took part in Fight Bladder Cancer's Bubbles for Bladder Cancer initiative. Prokarium is currently enrolling patients in our PARADIGM-1 clinical trial in the US for the treatment of non-muscle invasive bladder cancer.

Prokarium is proud to share our latest article, "Programmable Cancer Treatments: Engineering Biology Approaches for Living Cures", highlighting the vast potential of hashtag#syntheticbiology in revolutionizing hashtag#cancertherapy. Full article here : lnkd.in/eFZerP7F

Marc Biarnes Carrera, Head of Discovery, Synthetic Biology, will be presenting a poster at SEED on Wednesday the 26th June.

🚀Bladder Cancer Market Insight Series This week, we're diving into critical statistics about bladder cancer diagnosis in the US. Did you know that bladder cancer is the 6th most common? Understanding these numbers is vital for driving innovation and improving patient outcomes.

Bladder Cancer Market Insight Series This week, we are focusing on prevalence and the standard-of-care. Understanding survival rates reveals critical gaps in the lack of therapeutic options for patients living with bladder cancer.

Bladder Cancer Market Insight Series We're shedding light on crucial challenges in the fight against bladder cancer. Bladder cancer has the highest lifetime treatment costs. It also has one of the highest recurrence rates among all cancers. #BladderCancer #Oncology

Rocky M. Cranenburgh| Prokarium Ltd | UK | Vaccines 2014 | OMICS Interna... youtu.be/ZrR7l9VSPc4 vía YouTube

Toward Killing Cancer with Bacteria | The Scientist Magazine® the-scientist.com/?articles.view…

Prokarium's $10 mio investment featured in FiercePharma - see fiercepharma.com/vaccines/proka…